Improving VEGF-targeted therapies through inhibition of COX-2/PGE(2) signaling

Antiangiogenic agents targeting the vascular endothelial growth factor A (VEGFA) pathway play an important role in current cancer treatment modalities but are limited by alternative angiogenesis mechanisms. Recent studies suggest that enhanced signaling through a COX-2/PGE(2) axis contributes to VEG...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Lihong, Croix, Brad St.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905212/
https://www.ncbi.nlm.nih.gov/pubmed/27308371
http://dx.doi.org/10.4161/23723548.2014.969154
_version_ 1782437229650509824
author Xu, Lihong
Croix, Brad St.
author_facet Xu, Lihong
Croix, Brad St.
author_sort Xu, Lihong
collection PubMed
description Antiangiogenic agents targeting the vascular endothelial growth factor A (VEGFA) pathway play an important role in current cancer treatment modalities but are limited by alternative angiogenesis mechanisms. Recent studies suggest that enhanced signaling through a COX-2/PGE(2) axis contributes to VEGF-independent tumor angiogenesis. Thus, COX-2/PGE(2) inhibition may potentiate VEGF therapies.
format Online
Article
Text
id pubmed-4905212
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-49052122016-06-15 Improving VEGF-targeted therapies through inhibition of COX-2/PGE(2) signaling Xu, Lihong Croix, Brad St. Mol Cell Oncol Author's View Antiangiogenic agents targeting the vascular endothelial growth factor A (VEGFA) pathway play an important role in current cancer treatment modalities but are limited by alternative angiogenesis mechanisms. Recent studies suggest that enhanced signaling through a COX-2/PGE(2) axis contributes to VEGF-independent tumor angiogenesis. Thus, COX-2/PGE(2) inhibition may potentiate VEGF therapies. Taylor & Francis 2014-12-12 /pmc/articles/PMC4905212/ /pubmed/27308371 http://dx.doi.org/10.4161/23723548.2014.969154 Text en © 2014 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Author's View
Xu, Lihong
Croix, Brad St.
Improving VEGF-targeted therapies through inhibition of COX-2/PGE(2) signaling
title Improving VEGF-targeted therapies through inhibition of COX-2/PGE(2) signaling
title_full Improving VEGF-targeted therapies through inhibition of COX-2/PGE(2) signaling
title_fullStr Improving VEGF-targeted therapies through inhibition of COX-2/PGE(2) signaling
title_full_unstemmed Improving VEGF-targeted therapies through inhibition of COX-2/PGE(2) signaling
title_short Improving VEGF-targeted therapies through inhibition of COX-2/PGE(2) signaling
title_sort improving vegf-targeted therapies through inhibition of cox-2/pge(2) signaling
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905212/
https://www.ncbi.nlm.nih.gov/pubmed/27308371
http://dx.doi.org/10.4161/23723548.2014.969154
work_keys_str_mv AT xulihong improvingvegftargetedtherapiesthroughinhibitionofcox2pge2signaling
AT croixbradst improvingvegftargetedtherapiesthroughinhibitionofcox2pge2signaling

Ejemplares similares